Vivici Fuels Future of Dairy Proteins with Landmark EIC Funding
June 24, 2026, 9:37 pm
Vivici secured €12.5 million from the European Innovation Council. This significant funding fuels precision fermentation for dairy proteins. The Dutch company scales its Vivitein portfolio. It provides sustainable, high-purity lactoferrin and beta-lactoglobulin. This accelerates global market access and supply for vital ingredients. Vivici addresses traditional dairy production challenges directly. It champions food system transformation. Operations expand in Europe, the US, and the UAE. This milestone propels next-generation protein solutions forward. Vivici makes innovation a commercial reality.
Vivici, a pioneer in precision fermentation, just secured substantial investment. The European Innovation Council (EIC) delivered €12.5 million. This funding is critical. It directly supports Vivici's strategic objectives. The EIC Accelerator program is highly selective. It backs Europe's most promising innovators. Vivici underwent rigorous evaluation. Expert investors and entrepreneurs judged its potential. The award validates Vivici's cutting-edge technology. It confirms its strong commercial trajectory. This marks a significant milestone for the food tech sector.
Precision fermentation reshapes protein production. It utilizes microorganisms. These tiny biological factories produce specific proteins. The process is remarkably efficient. It is inherently sustainable. This method bypasses traditional animal agriculture entirely. It offers unparalleled protein purity. It ensures a consistent, reliable supply. The environmental footprint shrinks dramatically. Precision fermentation stands as a key food technology. It offers solutions for global food challenges.
Vivici focuses intently on dairy protein ingredients. Its Vivitein portfolio leads the market. This includes Vivitein BLG. It is beta-lactoglobulin. This protein is a primary component of whey. Vivitein LF is another core product. It is lactoferrin. This acts as a powerful bioactive protein. Both are expertly crafted through precision fermentation. They offer superior functionality. They provide clean label solutions for manufacturers. Brands gain access to pure dairy proteins. Supply chain vulnerabilities are minimized. Costs are managed more effectively.
The company shows rapid commercial momentum. It recently launched Vivitein LF in the U.S. market. The product holds self-affirmed GRAS status. GRAS means "Generally Recognized As Safe." This ensures immediate regulatory compliance. Vivitein BLG achieved FDA GRAS status even earlier. This opened significant market pathways. These regulatory approvals are crucial. They build consumer and industry trust. They facilitate broader market adoption for precision-fermented ingredients.
Vivici leverages strong foundational expertise. It originated from a collaboration between Fonterra and DSM-Firmenich. These founders bring immense knowledge. They possess deep experience in dairy proteins. They also contribute industrial-scale biomanufacturing acumen. Vivici integrates cutting-edge technological advancements. Novel tech from Danish startup Enduro Genetics boosts its production capabilities. This dramatically increases titers and yields. These are vital metrics in biomanufacturing efficiency. Vivici leapfrogs many competitors. It achieves leading performance in the field.
The company aggressively pursues global expansion. It works with established European co-manufacturing partners. This ensures production capacity on the continent. Vivici also secured a critical U.S. production deal. Liberation Bioindustries will produce its proteins in Indiana. This establishes a robust North American supply chain. A strategic partnership with the Abu Dhabi Investment Office explores facilities in the UAE. This expands Vivici's reach to the Middle East. Vivici builds a resilient, diverse global supply network. Its strategy is comprehensive.
Vivici's overarching aim is commercial viability. It seeks to turn precision fermentation into a widespread reality. The goal is scalable, accessible dairy protein production. Food companies gain powerful new tools. They develop more sustainable, highly scalable products. Nutrition and wellness brands benefit directly. They create premium offerings. These new products avoid the inherent constraints of traditional dairy. Vivici actively champions food system innovation. It delivers high-quality, sustainable protein solutions.
This EIC funding provides essential capital. It accelerates research and development. It enables market expansion. It strengthens manufacturing capabilities. Vivici can move faster. It can meet escalating customer demand. The company is poised for significant growth. It addresses critical global needs. These include protein security and environmental sustainability. Vivici represents the future. It is driving the next wave of food technology. The world watches its progress. Its impact will be profound.
Vivici, a pioneer in precision fermentation, just secured substantial investment. The European Innovation Council (EIC) delivered €12.5 million. This funding is critical. It directly supports Vivici's strategic objectives. The EIC Accelerator program is highly selective. It backs Europe's most promising innovators. Vivici underwent rigorous evaluation. Expert investors and entrepreneurs judged its potential. The award validates Vivici's cutting-edge technology. It confirms its strong commercial trajectory. This marks a significant milestone for the food tech sector.
Precision fermentation reshapes protein production. It utilizes microorganisms. These tiny biological factories produce specific proteins. The process is remarkably efficient. It is inherently sustainable. This method bypasses traditional animal agriculture entirely. It offers unparalleled protein purity. It ensures a consistent, reliable supply. The environmental footprint shrinks dramatically. Precision fermentation stands as a key food technology. It offers solutions for global food challenges.
Vivici focuses intently on dairy protein ingredients. Its Vivitein portfolio leads the market. This includes Vivitein BLG. It is beta-lactoglobulin. This protein is a primary component of whey. Vivitein LF is another core product. It is lactoferrin. This acts as a powerful bioactive protein. Both are expertly crafted through precision fermentation. They offer superior functionality. They provide clean label solutions for manufacturers. Brands gain access to pure dairy proteins. Supply chain vulnerabilities are minimized. Costs are managed more effectively.
The company shows rapid commercial momentum. It recently launched Vivitein LF in the U.S. market. The product holds self-affirmed GRAS status. GRAS means "Generally Recognized As Safe." This ensures immediate regulatory compliance. Vivitein BLG achieved FDA GRAS status even earlier. This opened significant market pathways. These regulatory approvals are crucial. They build consumer and industry trust. They facilitate broader market adoption for precision-fermented ingredients.
Vivici leverages strong foundational expertise. It originated from a collaboration between Fonterra and DSM-Firmenich. These founders bring immense knowledge. They possess deep experience in dairy proteins. They also contribute industrial-scale biomanufacturing acumen. Vivici integrates cutting-edge technological advancements. Novel tech from Danish startup Enduro Genetics boosts its production capabilities. This dramatically increases titers and yields. These are vital metrics in biomanufacturing efficiency. Vivici leapfrogs many competitors. It achieves leading performance in the field.
The company aggressively pursues global expansion. It works with established European co-manufacturing partners. This ensures production capacity on the continent. Vivici also secured a critical U.S. production deal. Liberation Bioindustries will produce its proteins in Indiana. This establishes a robust North American supply chain. A strategic partnership with the Abu Dhabi Investment Office explores facilities in the UAE. This expands Vivici's reach to the Middle East. Vivici builds a resilient, diverse global supply network. Its strategy is comprehensive.
Vivici's overarching aim is commercial viability. It seeks to turn precision fermentation into a widespread reality. The goal is scalable, accessible dairy protein production. Food companies gain powerful new tools. They develop more sustainable, highly scalable products. Nutrition and wellness brands benefit directly. They create premium offerings. These new products avoid the inherent constraints of traditional dairy. Vivici actively champions food system innovation. It delivers high-quality, sustainable protein solutions.
This EIC funding provides essential capital. It accelerates research and development. It enables market expansion. It strengthens manufacturing capabilities. Vivici can move faster. It can meet escalating customer demand. The company is poised for significant growth. It addresses critical global needs. These include protein security and environmental sustainability. Vivici represents the future. It is driving the next wave of food technology. The world watches its progress. Its impact will be profound.